10-QPeriod: Q2 FY2024

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2024

Filed July 31, 2024For Securities:SYK

Summary

Stryker Corporation (SYK) reported strong financial performance for the second quarter and first half of 2024, demonstrating robust top-line growth and improved profitability. Net sales increased by 8.5% to $5.42 billion for the quarter and 9.1% to $10.67 billion for the first half, driven by solid unit volume increases across both the MedSurg and Neurotechnology and Orthopaedics and Spine segments. This growth was achieved despite ongoing macroeconomic challenges such as inflation and supply chain disruptions. Profitability metrics also showed positive trends. Gross profit margin remained strong, and operating income saw significant increases, particularly in the MedSurg and Neurotechnology segment. Diluted earnings per share (EPS) rose to $2.14 for the quarter and $4.19 for the six-month period, reflecting the company's operational efficiency and strategic execution. Stryker's balance sheet remains healthy, with ample liquidity to support ongoing operations and strategic initiatives, including acquisitions.

Financial Highlights

52 data points
Beta

Revenue

$5.42B

63.0% Gross Margin

Net Income

$825.00M

15.2% Net Margin

EPS (Diluted)

$2.14

Total Assets

$39.13B

Cash & Equivalents

$1.87B

Free Cash Flow

$481.00M

Financial Statements
Beta
Revenue$5.42B
Cost of Revenue$2.01B
Gross Profit$3.42B
R&D Expenses$363.00M
SG&A Expenses$1.83B
Operating Expenses$2.37B
Operating Income$1.05B
Interest Expense$96.00M
Net Income$825.00M
EPS (Basic)$2.17
EPS (Diluted)$2.14
Shares Outstanding (Basic)381.00M
Shares Outstanding (Diluted)385.40M

Key Highlights

  • 1Net sales increased by 8.5% year-over-year to $5.42 billion in Q2 2024 and 9.1% to $10.67 billion for the first six months of 2024.
  • 2Organic sales growth (excluding currency, acquisitions, and divestitures) was strong at 9.4% for Q2 and 9.8% for the first half of the year.
  • 3Gross profit margin was 63.0% in Q2 2024, a slight decrease from 63.7% in Q2 2023, primarily due to higher manufacturing and supply chain costs.
  • 4Diluted earnings per share (EPS) increased to $2.14 in Q2 2024, up from $1.93 in the prior year's quarter, and $4.19 for the first six months, up from $3.47.
  • 5The MedSurg and Neurotechnology segment showed robust growth, with net sales up 9.0% in Q2, while Orthopaedics and Spine saw a 7.9% increase.
  • 6The company acquired SERF SAS for $244 million in Q1 2024, strengthening its Joint Replacement business.
  • 7Operating income increased to $1,051 million in Q2 2024, up from $965 million in the prior year's quarter, with operating margin improving to 19.4% from 19.3%.

Frequently Asked Questions

Stryker's sales growth was primarily driven by an increase in unit volume across both its MedSurg and Neurotechnology and Orthopaedics and Spine segments. This indicates strong demand for its products despite broader economic headwinds.

While gross profit margin saw a slight decrease due to higher manufacturing and supply chain costs, Stryker managed to maintain strong operating income and improve its operating margin for the six-month period. This was achieved through disciplined expense management, particularly in SG&A, and favorable sales pricing and volume contributions.

Stryker maintains a strong financial position with $1.874 billion in cash and cash equivalents as of June 30, 2024. Current assets significantly exceeded current liabilities, indicating healthy short-term liquidity. The company has access to various funding sources, including operating cash flow and credit facilities, to support its needs.

The acquisition of SERF SAS in March 2024 contributed to the growth in the Orthopaedics and Spine segment. The company also noted the impact of acquisitions and divestitures in its constant currency sales growth calculations, which were minimal for the reported periods.